Bicyclic inhibitors of histone deacetylase

• US 10,519,149 B2
• Filed: 03/23/2018
• Issued: 12/31/2019
• Est. Priority Date: 01/11/2017
• Status: Active Grant

• Current Assignee: Alkermes Pharma Ireland Limited (Alkermes plc)
• Original Assignee: Rodin Therapeutics, Inc. (Alkermes Incorporated)
• Inventors: Fuller, Nathan Oliver, Lowe, III, John A.
• Primary Examiner(s): Ramachandran, Umamaheswari
• Application Number:
  US15/934,299
• Publication Number:
  US 20180215759A1
• Time in Patent Office: 648 Days
• CPC Class Codes: A61K 31/437 the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

Claims

1. A method of treating a condition in a subject selected from Alzheimer'"'"'s disease, Huntington'"'"'s disease, fronto-temporal lobar degeneration, Friedreich'"'"'s ataxia, post-traumatic stress disorder, Parkinson'"'"'s disease, Parkinson'"'"'s disease dementia, substance dependence recovery, memory or cognitive function disorder or impairment, neurological disorder with synaptic pathology, disorder of learning distinction, psychiatric disorders, cognitive function or impairment associated with Alzheimer'"'"'s disease, Lewy body dementia, schizophrenia, Rubinstein Taybi syndrome, Rett Syndrome, Fragile X, multiple sclerosis, age associated memory impairment, age related cognitive decline, and social, cognitive and learning disorders associated with autism, comprising administering to the subject in need thereof an effective amount a histone deacetylase (HDAC) inhibitor of the Formula:

2. A method of treating a condition in a subject selected from Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Parkinson'"'"'s disease dementia, Huntington'"'"'s disease, and Lewy body dementia, comprising administering to the subject in need thereof an effective amount a histone deacetylase (HDAC) inhibitor of the Formula:

3. A method of inhibiting histone deacetylase (HDAC) activity in a subject comprising the administering to the subject in need thereof an effective amount of a histone deacetylase inhibitor (HDAC) of the Formula: